Skip to main content
Erschienen in: International Journal of Clinical Oncology 2/2011

01.04.2011 | Review Article

Cryoimmunology for malignant bone and soft-tissue tumors

verfasst von: Hideji Nishida, Norio Yamamoto, Yoshikazu Tanzawa, Hiroyuki Tsuchiya

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Several new methods have recently been developed for the treatment of malignant bone and soft-tissue tumors, and many of these targeted therapies have yielded promising initial results in clinical settings. As more sarcomas become amenable to effective molecular-targeting therapy, the need to evaluate the synergistic effects of combination therapies with anticancer drugs will grow. Other immunologic therapies have also been reported, such as exogenous cytokines, dendritic cell (DC) therapy and peptide vaccines. Cryoimmunology has shown promising results in some malignant tumors after cryosurgery and is expected to influence the next generation of tumor immunotherapy. In this report, we describe the induction of a systemic antitumor immune response following liquid nitrogen cryotreatment of a destructive murine osteosarcoma. Combining tumor cryotreatment with DCs to promote tumor-specific immune responses enhanced systemic immune responses and inhibited metastatic tumor growth. We also describe the induction of a systemic antitumor immune response following reconstruction for malignant bone tumors using frozen autografts treated with liquid nitrogen.
Literatur
1.
Zurück zum Zitat Bacci G, Longhi A, Versari M et al (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106:1154–1161PubMedCrossRef Bacci G, Longhi A, Versari M et al (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106:1154–1161PubMedCrossRef
2.
Zurück zum Zitat Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790PubMedCrossRef Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790PubMedCrossRef
3.
Zurück zum Zitat Meyers PA, Schwartz CL, Krailo M et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–2011PubMedCrossRef Meyers PA, Schwartz CL, Krailo M et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004–2011PubMedCrossRef
4.
Zurück zum Zitat Provisor AJ, Ettinger LJ, Nachman JB et al (1997) Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 15:76–84PubMed Provisor AJ, Ettinger LJ, Nachman JB et al (1997) Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 15:76–84PubMed
5.
Zurück zum Zitat Tsuchiya H, Yasutake H, Yokogawa A et al (1992) Effect of chemotherapy combined with caffeine for osteosarcoma. J Cancer Res Clin Oncol 118:567–569PubMedCrossRef Tsuchiya H, Yasutake H, Yokogawa A et al (1992) Effect of chemotherapy combined with caffeine for osteosarcoma. J Cancer Res Clin Oncol 118:567–569PubMedCrossRef
6.
Zurück zum Zitat Tsuchiya H, Tomita K, Mori Y et al (1999) Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop Relat Res 358:27–35PubMedCrossRef Tsuchiya H, Tomita K, Mori Y et al (1999) Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop Relat Res 358:27–35PubMedCrossRef
7.
Zurück zum Zitat Tsuchiya H, Tomita K, Mori Y et al (1998) Caffeine-assisted chemotherapy and minimized tumor excision for non-metastatic osteosarcoma. Anticancer Res 18:657–666PubMed Tsuchiya H, Tomita K, Mori Y et al (1998) Caffeine-assisted chemotherapy and minimized tumor excision for non-metastatic osteosarcoma. Anticancer Res 18:657–666PubMed
8.
Zurück zum Zitat Tsuchiya H, Kanazawa Y, Abdel-Wanis ME et al (2002) Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol 20:3470–3477PubMedCrossRef Tsuchiya H, Kanazawa Y, Abdel-Wanis ME et al (2002) Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma: the Japanese Musculoskeletal Oncology Group study. J Clin Oncol 20:3470–3477PubMedCrossRef
9.
Zurück zum Zitat Pacey S, Ratain MJ, Flaherty KT et al (2011) Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs [Epub ahead of print] Pacey S, Ratain MJ, Flaherty KT et al (2011) Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs [Epub ahead of print]
10.
Zurück zum Zitat Maki RG, D’Adamo DR, Keohan ML et al (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27:3133–3140PubMedCrossRef Maki RG, D’Adamo DR, Keohan ML et al (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27:3133–3140PubMedCrossRef
11.
Zurück zum Zitat Kuenen BC, Tabernero J, Baselga J et al (2003) Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 9:1648–1655PubMed Kuenen BC, Tabernero J, Baselga J et al (2003) Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 9:1648–1655PubMed
12.
Zurück zum Zitat Stopeck A, Sheldon M, Vahedian M et al (2002) Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 8:2798–2805PubMed Stopeck A, Sheldon M, Vahedian M et al (2002) Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 8:2798–2805PubMed
13.
Zurück zum Zitat D’Adamo DR, Anderson SE, Albritton K et al (2005) Phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas. J Clin Oncol 23:7135–7142PubMedCrossRef D’Adamo DR, Anderson SE, Albritton K et al (2005) Phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas. J Clin Oncol 23:7135–7142PubMedCrossRef
14.
Zurück zum Zitat Fuller CK, Charlson JA, Dankle SK et al (2010) Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. J Am Acad Dermatol 63:83–84CrossRef Fuller CK, Charlson JA, Dankle SK et al (2010) Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. J Am Acad Dermatol 63:83–84CrossRef
15.
Zurück zum Zitat Jordan K, Wolf HH, Voigt W et al (2010) Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. Bone Marrow Transplant 45:1704–1709PubMedCrossRef Jordan K, Wolf HH, Voigt W et al (2010) Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. Bone Marrow Transplant 45:1704–1709PubMedCrossRef
16.
Zurück zum Zitat Sleijfer S, Ray-Coquard I, Papai Z et al (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27:3126–3132PubMedCrossRef Sleijfer S, Ray-Coquard I, Papai Z et al (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27:3126–3132PubMedCrossRef
17.
Zurück zum Zitat Sugiura H, Fujiwara Y, Ando M et al (2010) Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci 15:654–660PubMedCrossRef Sugiura H, Fujiwara Y, Ando M et al (2010) Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci 15:654–660PubMedCrossRef
18.
Zurück zum Zitat Grignani G, Palmerini E, Stacchiotti S et al (2010) A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: an Italian Sarcoma Group study. Cancer 117:826–831PubMedCrossRef Grignani G, Palmerini E, Stacchiotti S et al (2010) A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: an Italian Sarcoma Group study. Cancer 117:826–831PubMedCrossRef
19.
Zurück zum Zitat Luksch R, Perotti D, Cefalo G et al (2003) Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori 3:263–268 Luksch R, Perotti D, Cefalo G et al (2003) Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori 3:263–268
20.
Zurück zum Zitat Geiger J, Hutchinson R, Hohenkirk L et al (2000) Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 356:1163–1165PubMedCrossRef Geiger J, Hutchinson R, Hohenkirk L et al (2000) Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 356:1163–1165PubMedCrossRef
21.
Zurück zum Zitat Tabarkiewicz J, Radej S, Hus I et al (2008) Dendritic cells based immunotherapy of patient with chondrosarcoma—case report. Folia Histochem Cytobiol 46:165–170PubMedCrossRef Tabarkiewicz J, Radej S, Hus I et al (2008) Dendritic cells based immunotherapy of patient with chondrosarcoma—case report. Folia Histochem Cytobiol 46:165–170PubMedCrossRef
22.
Zurück zum Zitat Ohta H, Hashii Y, Yoneda A et al (2009) WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report. Pediatr Hematol Oncol 26:74–83PubMedCrossRef Ohta H, Hashii Y, Yoneda A et al (2009) WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report. Pediatr Hematol Oncol 26:74–83PubMedCrossRef
23.
Zurück zum Zitat Ayyoub M, Taub RN, Keohan ML et al (2004) The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 4:7PubMed Ayyoub M, Taub RN, Keohan ML et al (2004) The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 4:7PubMed
24.
Zurück zum Zitat Segal NH, Blachere NE, Guevara-Patino JA et al (2005) Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun 5:2PubMed Segal NH, Blachere NE, Guevara-Patino JA et al (2005) Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun 5:2PubMed
25.
Zurück zum Zitat Mackall CL, Rhee EH, Read EJ et al (2008) A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 14:4850PubMedCrossRef Mackall CL, Rhee EH, Read EJ et al (2008) A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res 14:4850PubMedCrossRef
27.
Zurück zum Zitat Flanders VL, Gervais DA (2010) Ablation of liver metastases: current status. J Vasc Interv Radiol 21:S214–S222PubMedCrossRef Flanders VL, Gervais DA (2010) Ablation of liver metastases: current status. J Vasc Interv Radiol 21:S214–S222PubMedCrossRef
28.
Zurück zum Zitat Huang A, McCall JM, Weston MD et al (2002) Phase I study of percutaneous cryotherapy for colorectal liver metastasis. Br J Surg 89:303–310PubMedCrossRef Huang A, McCall JM, Weston MD et al (2002) Phase I study of percutaneous cryotherapy for colorectal liver metastasis. Br J Surg 89:303–310PubMedCrossRef
29.
Zurück zum Zitat Chin JL, Lim D, Abdelhady M (2007) Review of primary and salvage cryo-ablation for prostate cancer. Cancer Control 14:231–237PubMed Chin JL, Lim D, Abdelhady M (2007) Review of primary and salvage cryo-ablation for prostate cancer. Cancer Control 14:231–237PubMed
30.
Zurück zum Zitat Atwell TD, Farrell MA, Callstrom MR et al (2007) Percutaneous cryo-ablation of large renal masses: technical feasibility and short-term outcome. AJR Am J Roentgenol 188:1195–1200PubMedCrossRef Atwell TD, Farrell MA, Callstrom MR et al (2007) Percutaneous cryo-ablation of large renal masses: technical feasibility and short-term outcome. AJR Am J Roentgenol 188:1195–1200PubMedCrossRef
31.
Zurück zum Zitat Sabel MS, Kaufman CS, Whitworth P et al (2004) Cryo-ablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. Ann Surg Oncol 11:542–549PubMedCrossRef Sabel MS, Kaufman CS, Whitworth P et al (2004) Cryo-ablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. Ann Surg Oncol 11:542–549PubMedCrossRef
32.
Zurück zum Zitat Karlsson JO, Cravalho EG, Borel Rinkes IH et al (1993) Nucleation and growth of ice crystals inside cultured hepatocytes during freezing in the presence of dimethyl sulfoxide. Biophys J 65:2524–2536PubMedCrossRef Karlsson JO, Cravalho EG, Borel Rinkes IH et al (1993) Nucleation and growth of ice crystals inside cultured hepatocytes during freezing in the presence of dimethyl sulfoxide. Biophys J 65:2524–2536PubMedCrossRef
33.
34.
Zurück zum Zitat Sidana A, Chowdhury WH, Fuchs EJ et al (2010) Cryoimmunotherapy in urologic oncology. Urology 75:1009–1014PubMedCrossRef Sidana A, Chowdhury WH, Fuchs EJ et al (2010) Cryoimmunotherapy in urologic oncology. Urology 75:1009–1014PubMedCrossRef
35.
Zurück zum Zitat Marcove RC, Miller TR, Cahan WC et al (1968) The treatment of primary and metastatic bone tumors by repetitive freezing. Acad Med 44:532–544 Marcove RC, Miller TR, Cahan WC et al (1968) The treatment of primary and metastatic bone tumors by repetitive freezing. Acad Med 44:532–544
36.
Zurück zum Zitat Biesecker JL, Marcove RC, Huvos AG et al (1970) Aneurysmal bone cysts. A clinicopathologic study of 66 cases. Cancer 26:615–625PubMedCrossRef Biesecker JL, Marcove RC, Huvos AG et al (1970) Aneurysmal bone cysts. A clinicopathologic study of 66 cases. Cancer 26:615–625PubMedCrossRef
37.
Zurück zum Zitat Marcove RC, Weis LD, Vaghaiwalla MR et al (1978) Cryosurgery in the treatment of giant cell tumors of bone. A report of 52 consecutive cases. Cancer 41:957–969PubMedCrossRef Marcove RC, Weis LD, Vaghaiwalla MR et al (1978) Cryosurgery in the treatment of giant cell tumors of bone. A report of 52 consecutive cases. Cancer 41:957–969PubMedCrossRef
38.
Zurück zum Zitat Huvos AG, Marcove RC (1973) Chondroblastoma of bone. A critical review. Clin Orthop Relat Res 95:300–312PubMedCrossRef Huvos AG, Marcove RC (1973) Chondroblastoma of bone. A critical review. Clin Orthop Relat Res 95:300–312PubMedCrossRef
39.
Zurück zum Zitat Marcove RC, Miké V, Hutter RV et al (1972) Chondrosarcoma of the pelvis and upper end of the femur. An analysis of factors influencing survival time in one hundred and thirteen cases. J Bone Joint Surg Am 54:561–572PubMed Marcove RC, Miké V, Hutter RV et al (1972) Chondrosarcoma of the pelvis and upper end of the femur. An analysis of factors influencing survival time in one hundred and thirteen cases. J Bone Joint Surg Am 54:561–572PubMed
40.
Zurück zum Zitat Marcove RC, Abou Zahr K, Huvos AG et al (1984) Cryosurgery in osteogenic sarcoma: report of three cases. Compr Ther 10:52–60PubMed Marcove RC, Abou Zahr K, Huvos AG et al (1984) Cryosurgery in osteogenic sarcoma: report of three cases. Compr Ther 10:52–60PubMed
41.
Zurück zum Zitat Tsuchiya H, Wan SL, Sakayama K et al (2005) Reconstruction using an autograft containing tumour treated by liquid nitrogen. J Bone Joint Surg Br 87:218–225PubMed Tsuchiya H, Wan SL, Sakayama K et al (2005) Reconstruction using an autograft containing tumour treated by liquid nitrogen. J Bone Joint Surg Br 87:218–225PubMed
42.
Zurück zum Zitat Tsuchiya H, Nishida H, Srisawat P et al (2010) Pedicle frozen autograft reconstruction in malignant bone tumors. J Orthop Sci 15:340–349PubMedCrossRef Tsuchiya H, Nishida H, Srisawat P et al (2010) Pedicle frozen autograft reconstruction in malignant bone tumors. J Orthop Sci 15:340–349PubMedCrossRef
43.
Zurück zum Zitat Yantorno C, Soanes WA, Gonder MJ et al (1967) Studies in cryoimmunology. I. The production of antibodies to urogenital tissue in consequence of freezing treatment. Immunology 12:395–410PubMed Yantorno C, Soanes WA, Gonder MJ et al (1967) Studies in cryoimmunology. I. The production of antibodies to urogenital tissue in consequence of freezing treatment. Immunology 12:395–410PubMed
44.
Zurück zum Zitat Shulman S, Brandt EJ, Yantorno C (1968) Studies in cryo-immunology. II. Tissue and species specificity of the autoantibody response and comparison with iso-immunization. Immunology 14:149–158PubMed Shulman S, Brandt EJ, Yantorno C (1968) Studies in cryo-immunology. II. Tissue and species specificity of the autoantibody response and comparison with iso-immunization. Immunology 14:149–158PubMed
46.
Zurück zum Zitat Soanes WA, Gonder MJ, Ablin RJ (1970) A possible immuno-cryothermic response in prostatic cancer. Clin Radiol 21:253–255PubMedCrossRef Soanes WA, Gonder MJ, Ablin RJ (1970) A possible immuno-cryothermic response in prostatic cancer. Clin Radiol 21:253–255PubMedCrossRef
47.
Zurück zum Zitat Neel HB III, Ketcham AS, Hammond WG (1973) Experimental evaluation of in situ oncocide for primary tumor therapy: comparison of tumor-specific immunity after complete excision, cryonecrosis and ligation. Laryngoscope 83:376–387PubMedCrossRef Neel HB III, Ketcham AS, Hammond WG (1973) Experimental evaluation of in situ oncocide for primary tumor therapy: comparison of tumor-specific immunity after complete excision, cryonecrosis and ligation. Laryngoscope 83:376–387PubMedCrossRef
48.
Zurück zum Zitat Bagley DH, Faraci RP, Marrone JC et al (1974) Lymphocyte mediated cytotoxicity after cryosurgery of a murine sarcoma. J Surg Res 17:404–406PubMedCrossRef Bagley DH, Faraci RP, Marrone JC et al (1974) Lymphocyte mediated cytotoxicity after cryosurgery of a murine sarcoma. J Surg Res 17:404–406PubMedCrossRef
49.
Zurück zum Zitat Misao A, Sakata K, Saji S et al (1981) Late appearance of resistance to tumor rechallenge following cryosurgery. A study in an experimental mammary tumor of the rat. Cryobiology 18:386–389PubMedCrossRef Misao A, Sakata K, Saji S et al (1981) Late appearance of resistance to tumor rechallenge following cryosurgery. A study in an experimental mammary tumor of the rat. Cryobiology 18:386–389PubMedCrossRef
50.
Zurück zum Zitat Joosten JJ, Muijen GN, Wobbes T et al (2001) In vivo destruction of tumor tissue by cryoablation can induce inhibition of secondary tumor growth: an experimental study. Cryobiology 42:49–58PubMedCrossRef Joosten JJ, Muijen GN, Wobbes T et al (2001) In vivo destruction of tumor tissue by cryoablation can induce inhibition of secondary tumor growth: an experimental study. Cryobiology 42:49–58PubMedCrossRef
51.
Zurück zum Zitat Sabel MS, Nehs MA, Su G et al (2005) Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat 90:97–104PubMedCrossRef Sabel MS, Nehs MA, Su G et al (2005) Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat 90:97–104PubMedCrossRef
52.
53.
Zurück zum Zitat den Brok MH, Sutmuller RP, Nierkens S et al (2006) Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 95:896–905CrossRef den Brok MH, Sutmuller RP, Nierkens S et al (2006) Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 95:896–905CrossRef
54.
Zurück zum Zitat Urano M, Tanaka C, Sugiyama Y et al (2003) Anti-tumor effects of residual tumor after cryo-ablation: the combined effect of residual tumor and a protein-bound polysaccharide on multiple liver metastases in a murine model. Cryobiology 46:238–245PubMedCrossRef Urano M, Tanaka C, Sugiyama Y et al (2003) Anti-tumor effects of residual tumor after cryo-ablation: the combined effect of residual tumor and a protein-bound polysaccharide on multiple liver metastases in a murine model. Cryobiology 46:238–245PubMedCrossRef
55.
Zurück zum Zitat Lubaroff DM, Reynolds CM, Canfield L (1981) Immunologic aspects of the prostate. Prostate 23:233–248CrossRef Lubaroff DM, Reynolds CM, Canfield L (1981) Immunologic aspects of the prostate. Prostate 23:233–248CrossRef
56.
Zurück zum Zitat Udagawa M, Saito CK, Hasegawa G et al (2006) Enhancement of immunologic tumor regression by intra-tumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and bacillus Calmette–Guerin cell wall skeleton stimulation. Clin Cancer Res 12:7465–7475PubMedCrossRef Udagawa M, Saito CK, Hasegawa G et al (2006) Enhancement of immunologic tumor regression by intra-tumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and bacillus Calmette–Guerin cell wall skeleton stimulation. Clin Cancer Res 12:7465–7475PubMedCrossRef
57.
Zurück zum Zitat Machlenkin A, Goldberger O, Tirosh B et al (2005) Combined dendritic cell cryosurgery of tumor induces systemic antimetastatic immunity. Clin Cancer Res 11:4955–4961PubMedCrossRef Machlenkin A, Goldberger O, Tirosh B et al (2005) Combined dendritic cell cryosurgery of tumor induces systemic antimetastatic immunity. Clin Cancer Res 11:4955–4961PubMedCrossRef
58.
Zurück zum Zitat Osada S, Imai H, Tomita H et al (2007) Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol 95:491–498PubMedCrossRef Osada S, Imai H, Tomita H et al (2007) Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol 95:491–498PubMedCrossRef
59.
Zurück zum Zitat Nishida H, Tsuchiya H, Tomita K (2008) Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma. J Bone Joint Surg Br 90:1249–1255PubMedCrossRef Nishida H, Tsuchiya H, Tomita K (2008) Re-implantation of tumour tissue treated by cryotreatment with liquid nitrogen induces anti-tumour activity against murine osteosarcoma. J Bone Joint Surg Br 90:1249–1255PubMedCrossRef
60.
Zurück zum Zitat Kawano M, Nishida H, Nakamoto Y et al (2010) Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma. Clin Orthop Relat Res 468:1373–1383PubMedCrossRef Kawano M, Nishida H, Nakamoto Y et al (2010) Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma. Clin Orthop Relat Res 468:1373–1383PubMedCrossRef
Metadaten
Titel
Cryoimmunology for malignant bone and soft-tissue tumors
verfasst von
Hideji Nishida
Norio Yamamoto
Yoshikazu Tanzawa
Hiroyuki Tsuchiya
Publikationsdatum
01.04.2011
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 2/2011
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0218-2

Weitere Artikel der Ausgabe 2/2011

International Journal of Clinical Oncology 2/2011 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.